In a population-based study of 2982 bladder cancer patients and 5782 population controls from 10 geographical areas of the US, no excess risk was associated with medications used for tuberculosis treatment or prophylaxis (relative risk (RR) = 0.95). The findings agree with other epidemiological studies that have not confirmed earlier reports linking isoniazid (INH) exposure to bladder cancer.